ANALYSIS OF THE RESULTS OF DIAGNOSIS AND TREATMENT OF BREAST CANCER IN YOUNG WOMEN

##plugins.themes.bootstrap3.article.main##

Abstrak:





This article presents a comprehensive analysis of the results from a detailed study focused on breast cancer (BC) in young women, a demographic with distinct clinical and biological challenges. The research entailed an in-depth examination of the clinical presentation, morphological characteristics, and biological profiles of tumors in this patient group. A key objective was to evaluate the efficacy of various contemporary treatment regimens employed in their management. Through rigorous statistical analysis, the study successfully identified critical factors that significantly impact both overall survival (OS) and recurrence-free survival (RFS). Building upon these findings, the article proposes refined and optimal treatment strategies that meticulously integrate the specific biological subtype of the tumor, such as hormone receptor status, HER2/neu amplification, and triple-negative phenotype, with the unique considerations of the patient's age, including fertility preservation and long-term quality of life. The conclusions underscore the necessity of a personalized, multidisciplinary approach to improve prognostic outcomes and address the comprehensive needs of young women diagnosed with breast cancer.





##plugins.themes.bootstrap3.article.details##

##submission.citations##:

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687-1717.

Pagani O., et al. Impact of SERM and ovarian suppression on breast cancer recurrence in premenopausal women: results from the SOFT trial. N Engl J Med. 2014;371:107-118.

Lambertini M., et al. Pregnancy after breast cancer: a systematic review and meta-analysis. J Clin Oncol. 2021;39:3293-3305.

Sung H., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-249.

Partridge AH., et al. Ovarian suppression in premenopausal breast cancer: long-term follow-up of the TEXT and SOFT trials. J Clin Oncol. 2023;41:15-23.

Francis PA., et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2015;372:436-446.

Cardoso F., et al. Early breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2019;30:1194-1220.

Burstein HJ., et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Expert Consensus. Ann Oncol. 2021;32:1216-1235.

Loibl S., et al. Breast cancer in young women: epidemiology, treatment, and outcome. Breast Care. 2020;15:481-489.

Paluch-Shimon S., et al. ESO-ESMO International Consensus Guidelines for Breast Cancer in Young Women (BCY4). Ann Oncol. 2020;31:674-696.